Neuren Pharma ( NEU.AX)
Marketcap: only 48 million A$
Price: 0,34 A$
Awesome Pipeline :
Glypromate MCI in CABG Phase 3
NNZ-2566 Severe TBI Phase 2a (deal with US Army)
NNZ-2566 Mild/Mod TBI Phase 2
Motiva Apathy Phase 2b
Taylor Collison
http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf
By the end 1Q CY08, we expect Neuren to be running four major
efficacy trials; namely three Phase 2 trials for NNZ-2566 in
mild/moderate and severe TBI and Motiva™ in post stroke abulia/
depression coupled with the current Phase 3 trial for Glypromate® in
CABG. All indications potentially provide Neuren with first to market,
billion dollar opportunities. With a current market cap of $40.2m, Neuren
remains a solid value proposition in the sector, where FDA INDs for mid
to late stage clinical trials continues to remain a vexing proposition. We
maintain our Speculative Buy recommendation and price target of $1.30,
though expect to make changes to our valuation model once the
acquisition has closed, which we expect during the current Q.
- Forums
- ASX - By Stock
- SNT
- cheapest biotech stock on the asx
cheapest biotech stock on the asx
-
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $59.04M |
Open | High | Low | Value | Volume |
4.3¢ | 4.3¢ | 4.2¢ | $20.22K | 474.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 25780 | 4.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.4¢ | 581744 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 25780 | 0.042 |
3 | 431774 | 0.041 |
5 | 775000 | 0.040 |
1 | 750000 | 0.039 |
3 | 157644 | 0.038 |
Price($) | Vol. | No. |
---|---|---|
0.044 | 581744 | 4 |
0.045 | 450250 | 1 |
0.046 | 1100000 | 2 |
0.047 | 20000 | 1 |
0.049 | 68444 | 2 |
Last trade - 15.54pm 11/10/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |